Ansell Limited

This year's Phoenix Lifetime Achievement award winner is interviewed about how he successfully ran both major device and drug businesses and retired early to tell about it. by Stephen Levin The curren

St. Jude's valuation took some big hits during a tumultuous acquisition campaign to diversify the stagnating one-product company. But the strategy worked. by Stephen Levin In the early 1990s, St. Paul

For some, it further separates the haves and have-nots. For others, it's an addictive drug for coping with chronic insufficiency syndrome. by Roger Longman All roads in 1998, it sometimes seemed, led

In the following interviews, experts from the pharmaceutical, medical device and diagnostics industries, as well as two fund managers focused on small-cap stocks, look back on this past year's trials